Alector, GSK to end partnership after dementia and Alzheimer’s drug setbacks

• Alector received $700 million upfront in 2021 and was eligible for up to $1.5 billion in milestone payments and royalties that will now not materialize
• Latozinemab failed a late-stage trial for frontotemporal dementia, prompting Alector to cut nearly half its workforce
• The termination follows a 180-day notice period initiated July 6, with the partnership officially ending January 2, 2026

Summary: Alector-GSK Partnership Termination Following Dementia Drug Failures

Key Development: GSK has terminated its neuroscience collaboration with Alector following clinical failures of two experimental antibody drugs targeting dementia and Alzheimer's disease. The termination becomes effective January 2, 2026, after a 180-day notice period that began July 6, 2025.

Failed Drug Candidates:

• Latozinemab: Failed late-stage clinical trial for treating a rare inherited form of frontotemporal dementia
• Nivisnebart: Discontinued after interim analysis indicated the study would unlikely meet its primary endpoint

Financial Terms:

The partnership, established in 2021, included significant financial commitments:

• Alector received $700 million upfront payment from GSK
• Deal structure allowed for up to $1.5 billion in potential milestone payments and royalties
• These future payments will no longer materialize due to the termination

Business Impact:

• Alector has already cut nearly half its workforce following latozinemab's failure
• The collaboration covered monoclonal antibody development under a 2021 license agreement
• Both companies exit the partnership with no successful drug candidates

Market Implications:

This termination represents a significant setback in neuroscience drug development, particularly for treatments targeting rare forms of dementia and Alzheimer's disease. The failure highlights ongoing challenges in developing effective therapies for neurodegenerative diseases, a sector that has seen numerous high-profile clinical disappointments. For Alector, the loss of potential milestone payments and the earlier workforce reduction signal substantial operational and financial restructuring ahead.